Allakos Inc. (ALLK)’s Financial Results Comparing With Immunic Inc. (NASDAQ:IMUX)

Both Allakos Inc. (NASDAQ:ALLK) and Immunic Inc. (NASDAQ:IMUX) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allakos Inc. 51 0.00 N/A -1.27 0.00
Immunic Inc. 13 0.00 N/A -34.26 0.00

In table 1 we can see Allakos Inc. and Immunic Inc.’s gross revenue, earnings per share and valuation.


Table 2 provides us the return on equity, return on assets and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Allakos Inc. 0.00% -46.6% -33.6%
Immunic Inc. 0.00% -235.3% -182.3%


The Current Ratio of Allakos Inc. is 20.5 while its Quick Ratio stands at 20.5. The Current Ratio of rival Immunic Inc. is 7 and its Quick Ratio is has 7. Allakos Inc. is better equipped to clear short and long-term obligations than Immunic Inc.

Analyst Recommendations

In next table is delivered Allakos Inc. and Immunic Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Allakos Inc. 0 0 0 0.00
Immunic Inc. 0 0 1 3.00

Immunic Inc. on the other hand boasts of a $40 average price target and a 223.36% potential upside.

Institutional & Insider Ownership

The shares of both Allakos Inc. and Immunic Inc. are owned by institutional investors at 97.4% and 1.6% respectively. Comparatively, insiders own roughly 0.3% of Immunic Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Allakos Inc. 4.23% -20.78% -7.77% -10.87% -13.08% -33.48%
Immunic Inc. 1.94% 21.1% 2.94% 71.52% -95.65% 83.31%

For the past year Allakos Inc. has -33.48% weaker performance while Immunic Inc. has 83.31% stronger performance.


On 5 of the 7 factors Allakos Inc. beats Immunic Inc.

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.